Emestop 40 mg (Capsule)
Unit Price: ৳ 50.00 (1 x 4: ৳ 200.00)
Strip Price: ৳ 200.00
Medicine Details
Category | Details |
---|---|
Generic | Aprepitant |
Company | Incepta pharmaceuticals ltd |
Also available as |
Title
- Emestop
Categories
- Medicine
- Health
- Pharmacology
- Antiemetic
Description
- Emestop is indicated for prevention of postoperative nausea and vomiting (PONV) and prevention of Chemotherapy Induced Nausea and Vomiting (CINV). Aprepitant, the active ingredient, is a selective high affinity antagonist of human substance P neurokinin 1 (NK1) receptors, which blocks the receptors to prevent nausea and vomiting. It is available in various dosage regimens for different indications. Emestop is a substrate, a weak-to-moderate inhibitor, and an inducer of CYP3A4, and an inducer of CYP2C9, and should be stored below 30°C, away from light & moisture.
Dimensions
- N/A
Color options
- N/A
Functions
- Prevention of postoperative nausea and vomiting (PONV)
- Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
Materials
- Aprepitant
Technical specifications
- Aprepitant 40 mg oral dosage within 3 hours prior to induction of anesthesia for PONV
- Aprepitant 125 mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron) regimen for highly emetogenic cancer chemotherapy for CINV
- Aprepitant 80 mg orally, Dexamethasone 8 mg orally regimen for moderately emetogenic cancer chemotherapy for CINV
Design elements
- N/A
Usability features
- May be taken with or without food
- No dosage adjustment necessary for elderly patients
- No dosage adjustment necessary for patients with renal impairment or end-stage renal disease (ESRD) undergoing hemodialysis
- No dosage adjustment necessary for patients with mild to moderate hepatic impairment
Interaction
- Emestop is a substrate, a weak-to-moderate (dose dependent) inhibitor, and an inducer of CYP3A4
- Emestop is also an inducer of CYP2C9
- Precautions should be taken while coadministering Emestop with drugs that use CYP3A4 or CYP2C9
- Coadministration may affect the efficacy of hormonal contraceptives, alternative or back-up methods of contraception should be used during treatment with Emestop and for 1 month following the last dose
Contraindications
- Hypersensitivity to any component of the product
- Concurrent use with Pimozide, Terfenadine, Astemizole, & Cisapride
Side effects
- Constipation
- Hypotension
- Pruritus
- Pyrexia
Pregnancy lactation
- Pregnancy Category B
- Use during pregnancy only if clearly needed
- Not known whether excreted in human milk
- Decision to discontinue nursing or drug based on patient's importance
Special populations
- No dosage adjustment necessary for patients with renal impairment or ESRD undergoing hemodialysis
- No dosage adjustment necessary for patients with mild to moderate hepatic impairment
- No clinical data in patients with severe hepatic impairment
Overdose effects
- No specific information available on the treatment of overdosage with Emestop
- Drowsiness and headache may result from overdose
- Emestop should be discontinued in the event of overdose
- General supportive treatment and monitoring should be provided
- Medicine-induced emesis may not be effective due to antiemetic activity of Emestop
- Emestop cannot be removed by hemodialysis
Therapeutic class
- Anti-emetic drugs
Storage conditions
- Keep below 30°C temperature
- Away from light & moisture
- Keep out of the reach of children